Detect Earlier, Monitor Smarter, Act Faster
Harness Liquid Biopsies to Optimize Patient & Dose Selection, Strengthen Trial Design & Accelerate Smarter, More Precise Clinical Decisions
As liquid biopsies become increasingly integral to clinical trials, and with their full potential still to be defined, the 5th Liquid Biopsy for Precision Oncology Summit East Coast returns at a pivotal moment to bring these conversations into sharp focus.
Set to be our largest and most comprehensive meeting to date, this the year to reconvene with the wider liquid biopsy community and take the next step in implementation across clinical development and into routine care.
Look forward to in-depth presentations and interactive discussions on patient selection, dose optimization, companion diagnostic development, ultra-sensitive assays and more. Join 130+ senior experts in shaping the future of precision medicine to detect earlier, monitor smarter and act faster, ultimately improving patient outcomes and lives.
The quality of the presentations was fantastic. There was ample opportunity for Q&A during and after the lecture, which meant I came out of the conference with actionable ideas
Chief Scientific Officer, Aveta Biomics, Past Attendee
The in-depth discussions on emerging topics in liquid biopsy, especially its role in clinical trial design and patient stratification, were both timely and thought-provoking
Scientific Expert, Harvard Medical School, Past Attendee
The summit provided a very strong and focused exchange around ctDNA innovation and MRD evolution, particularly in the context of assay sensitivity, clinical validation, and integration into oncology workflows. The level of scientific rigor and the openness of discussion around technical limitations, tumor heterogeneity, and real-world implementation challenges were especially valuable
Chief Executive Officer, Biopsomic, Past Attendee
This is my second or third time attending this meeting, and I have seen tremendous progress in the field, from technological advances through to emerging scientific insights.
The meeting provided a valuable opportunity to stay current, broaden my knowledge, and ultimately apply these advances to our clinical studies
Executive Director, Fore Biotherapeutics, Past Attendee
The meeting was well organized with balanced talks and discussions. It covered the latest advances and trends of the field and allowed for meaningful interactions with multiple stakeholders
Distinguished Scientist, Genentech, Past Attendee
A Preview of the Speaker Faculty
Delve into the Brand-New Agenda
- Find the full speaker faculty, featuring senior leaders from Pfizer, AbbVie, Takeda, AstraZeneca, GSK and more
- Plan your 2026 experience, identify the sessions you cannot miss and map the partners to meet
- Gain exclusive insights into MRD as a regulatory endpoint, ctDNA-driven dose optimization, and AI-integration in precision oncology pipelines
- Unpack the complete details of our in-depth Pre-Conference Engager Sessions and register your interest before spots are filled
Program Partners
Who You Will Connect With
Explore the New Agenda
Discover the latest breakthroughs in ctDNA, MRD, methylation and multi-omic profiling through a focused program of expert presentations, interactive roundtables and strategic panel discussions driving precision oncology forward.
Stand at the Forefront of Liquid Biopsy Innovation
Position your solutions alongside leading diagnostic and technology providers to ensure your brand is central to the conversations shaping the next generation of oncology drug development.
Join Senior Biopharma & Diagnostic Leaders
Engage with decision-makers across translational medicine, precision oncology and clinical development, and build high-value connections during dedicated networking sessions designed to foster collaborations.